Corporate Profile
WuXi PharmaTech (pronounced woo-shee pharma-tek) is a leading global contract R&D services provider serving the pharmaceutical, biotech, and medical device industries. The company is headquartered in Shanghai and has operations in both China and the United States. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the R&D process. Our services are designed to help our global partners shorten the time and lower the cost of R&D. The parent company is known as WuXi PharmaTech, and its operating divisions are known as WuXi AppTec (pronounced woo-shee app-tek)... More >>
What's New
download pdf  Investor Fact Sheet
Recent NewsMore >>
DateTitle 
06/04/15WuXi AppTec Partners with Fudan University and the Collaborative Innovation Center of Genetics and Development
China's leading research and innovation cluster will use WuXi NextCODE technology, the world's most proven genomics system, to advance precision medicine SHANGHAI, CAMBRIDGE, Mass. and REYKJAVIK, Iceland, June 4, 2015 /PRNewswire/ -- WuXi AppTec today announced a partnership with Fudan University to bring WuXi NextCODE's world-leading population human genomics database system and integrated research and clinical solutions to the Fudan-led Collaborative Innovation Center of Genetics and Deve... 
Printer Friendly Version
06/03/15WuXi NextCODE Wins Genomics England Clinical Interpretation Tender in Both Rare Disease and Cancer
... 
Printer Friendly Version
05/21/15Fosun Pharma, HOPU Investments, CEL Healthcare Fund, and WuXi PharmaTech to Jointly Acquire U.S. Innovative Biotechnology Company Ambrx
SHANGHAI, May 21, 2015 /PRNewswire/ -- A consortium ("the Consortium") consisting of entities affiliated with Shanghai Fosun Pharmaceutical Group, HOPU Investments, China Everbright Limited's healthcare fund ("CEL Healthcare Fund"), and WuXi PharmaTech announced today that the Consortium has signed a merger agreement pursuant to which the Consortium will acquire Ambrx Inc. The transaction is expected to close in the second quarter of 2015, subject to receipt of certain regulatory approvals and s... 
Printer Friendly Version
05/21/15WuXi Launches e-Commerce Platform for Chemistry Products
SHANGHAI, May 21, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, today announced the launch of LabNetwork (www.labnetwork.com). LabNetwork is a global e-Commerce platform for connecting buyers and sellers of research chemicals and reagents. Backed by WuXi's world-class expertise in chemist... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Stock QuoteMore >>
WX (Common Stock)
ExchangeNYSE (US Dollar)
Price$41.82
Change (%) Stock is Down 0.17 (0.40%)
Volume338,077
Data as of 07/02/15 4:02 p.m. ET
Minimum 20 minute delay
Refresh quote
CalendarMore >>
July 2015?
Calendar Help
This calendar contains six months of past and future company related information, which may include press releases, SEC filings, calendar events and more. Dates containing information are indicated by a colored background. You may hover your mouse over a date that contains an event to reveal the event or events taking place on that day including a link to additional information. This calendar requires JavaScript to be installed and activated on your browser.
Calendar Icon Legend:
Analyst Meeting
Conference
Conference Presentation
Corporate Conference Call
Custom Events
Earnings Conference Call
Earnings Release
Financial Reports
Mergers & Acquisition Announcement
Guidance Announcement
Other Corporate
Sales Call/Presentation
Sales Release
Shareholders Meeting
News Release
SEC Filings
Presentations
52 Week High
Today
SunMonTueWedThuFriSat
-3-2-11234
567891011
12131415161718
19202122232425
26272829303151
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever WuXi PharmaTech (Cayman) Inc. posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.